Abstract
Mutations in BRAF, a component of extracellular signal-regulated kinases 1 and 2 (ERK) cascade, are frequent in melanoma. It is important to understand how BRAF mutations contribute to malignant traits including anchorage- and growth factor-independence. We have previously shown that efficient activation of ERK in normal human epidermal melanocytes (NHEM) requires both adhesion to the extracellular matrix and growth factors. Mutant V599E BRAF is sufficient to promote ERK activation independent of adhesion and growth factors. Here, we analysed regulation of G1 cell cycle events in NHEM and human melanoma cells. We show that S phase entry in NHEM requires both adhesion and growth factor signaling through the MEK-ERK pathway. This control correlates with induction of cyclin D1 and downregulation of p27Kip1, two key G1 cell cycle events. In melanoma cells expressing V599E BRAF, cyclin D1 was constitutively expressed independent of adhesion but dependent upon MEK activation and nuclear accumulation of ERK. Reduction of cyclin D1 levels by RNA interference inhibited S phase entry in melanoma cells. Importantly, expression of V599E BRAF in NHEM was sufficient to promote cyclin D1 promoter activity in the absence of adhesion. Additionally, p27Kip1 levels were downregulated in V599E BRAF-expressing melanoma cells and active BRAF was sufficient to downregulate p27Kip1 in serum-starved NHEM. Thus, adhesion-growth factor cooperation, leading to efficient activation of ERK, regulates cyclin D1 and p27Kip1 levels in human melanocytes and mutant BRAF overrides adhesion-growth factor control of these two G1 cell cycle proteins in melanomas. These findings provide important insight into how BRAF mutations contribute to aberrant human melanocyte proliferation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- CDK:
-
cyclin-dependent kinase
- ECM:
-
extracellular matrix
- ERK:
-
extracellular signal-regulated kinases 1 and 2
- MAPK:
-
mitogen-activated protein kinase
- MEK:
-
MAPK/ERK kinase
- NHEM:
-
normal human epidermal melanocytes
- RGP:
-
radial growth phase
- TPA:
-
12-O-tetradecanoyl phorbol 13-acetate
- VGP:
-
vertical growth phase
References
Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A and Pestell RG . (1995). J. Biol. Chem., 270, 23589–23597.
Assoian RK . (1997). J. Cell Biol., 136, 1–4.
Bartkova J, Lukas J, Strauss M and Bartek J . (1995). Oncogene, 10, 775–778.
Bottazzi ME, Zhu X, Bohmer RM and Assoian RK . (1999). J. Cell Biol., 146, 1255–1264.
Brunet A, Roux D, Lenormand P, Dowd S, Keyse S and Pouyssegur J . (1999). EMBO J., 18, 664–674.
Busse D, Doughty RS, Ramsey TT, Russell WE, Price JO, Flanagan WM, Shawver LK and Arteaga CL . (2000). J. Biol. Chem., 275, 6987–6995.
Cannon-Albright LA, Kamb A and Skolnick M . (1996). Semin. Oncol., 23, 667–672.
Carrano AC and Pagano M . (2001). J. Cell Biol., 153, 1381–1390.
Chin L . (2003). Nat. Rev. Cancer, 3, 559–570.
Collado M, Medema RH, Garcia-Cao I, Dubuisson ML, Barradas M, Glassford J, Rivas C, Burgering BM, Serrano M and Lam EW . (2000). J. Biol. Chem., 275, 21960–21968.
Collisson EA, De A, Suzuki H, Gambhir SS and Kolodney MS . (2003). Cancer Res., 63, 5669–5673.
Conner SR, Scott G and Aplin AE . (2003). J. Biol. Chem., 278, 34548–34554.
Coqueret O . (2002). Gene, 299, 35–55.
D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B, Fu M, Augenlicht LH, Donehower LA, Takemaru K, Moon RT, Davis R, Lisanti MP, Shtutman M, Zhurinsky J, Ben-Ze'ev A, Troussard AA, Dedhar S and Pestell RG . (2000). J. Biol. Chem., 275, 32649–32657.
Danen EH, Sonneveld P, Sonnenberg A and Yamada KM . (2000). J. Cell Biol., 151, 1413–1422.
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR and Futreal PA . (2002). Nature, 417, 949–954.
Delmas C, Aragou N, Poussard S, Cottin P, Darbon J-M and Manenti S . (2003). J. Biol. Chem., 278, 12443–12451.
Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z and Aaronson SA . (2003). Cancer Res., 63, 3883–3885.
Fang F, Orend G, Watanabe N, Hunter T and Ruoslahti E . (1996). Science, 271, 499–502.
Freedman VH and Shin SI . (1974). Cell, 3, 355–359.
Fujita N, Sato S, Katayama K and Tsuruo T . (2002). J. Biol. Chem., 277, 28706–28713.
Gille H and Downward J . (1999). J. Biol. Chem., 274, 22033–22040.
Govindarajan B, Bai X, Cohen C, Zhong H, Kilroy S, Louis G, Moses M and Arbiser JL . (2003). J. Biol. Chem., 278, 9790–9795.
Greulich H and Erikson RL . (1998). J. Biol. Chem., 273, 13280–13288.
Grinnell F . (1992). J. Cell Sci., 101, 1–5.
Groom LA, Sneddon AA, Alessi DR, Dowd S and Keyse SM . (1996). EMBOJ., 15, 3621–3632.
Hara M, Yaar M, Tang A, Eller MS, Reenstra W and Gilchrest BA . (1994). J. Cell Sci., 107, 2739–2748.
Hedley SJ, Wagner M, Bielby S, Smith-Thomas L, Gawkrodger DJ and MacNeil S . (1997). Pigment Cell Res., 10, 54–59.
Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M and Tuveson DA . (2003). Cancer Res., 63, 5198–5202.
Hynes RO . (2002). Cell, 110, 673–687.
Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR and Fisher PB . (1995). Oncogene, 10, 1855–1864.
Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ and Marais R . (2004). Oncogene, 23, 6292–6298.
Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S and Uehara Y . (1997). Oncogene, 15, 629–637.
Kortylewski M, Heinrich PC, Kauffmann ME, Bohm M, MacKiewicz A and Behrmann I . (2001). Biochem. J., 357, 297–303.
Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S and Hemminki K . (2003). Clin. Cancer Res., 9, 3362–3368.
Lai J-M, Wu S, Huang D-Y and Chang Z-F . (2002). Mol. Cell. Biol., 22, 7581–7592.
Lavoie JN, L'Allemain G, Brunet A, Muller R and Pouyssegur J . (1996). J. Biol. Chem., 271, 20608–20616.
Le Gall M, Grall D, Chambard JC, Pouyssegur J and Van Obberghen-Schilling E . (1998). Oncogene, 17, 1271–1277.
Malumbres M, Perez De Castro I, Hernandez MI, Jimenez M, Corral T and Pellicer A . (2000). Mol. Cell. Biol., 20, 2915–2925.
McMahon M . (2001). Methods Enzymol, 332, 401–417.
McMullen M, Keller R, Sussman M and Pumiglia K . (2004). Oncogene, 23, 1275–1282.
Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK and Giancotti FG . (2001). Mol. Cell, 8, 115–127.
Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN and Rosen N . (1998). J. Biol. Chem., 273, 29864–29872.
Pagano M, Pepperkok R, Verde F, Ansorge W and Draetta G . (1992). EMBO J, 11, 961–971.
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM and Meltzer PS . (2003). Nat. Genet., 33, 19–20.
Pruitt K and Der CJ . (2001). Cancer Lett, 171, 1–10.
Pumiglia KM and Decker SJ . (1997). Proc. Natl. Acad. Sci. USA, 94, 448–452.
Ravi RK, Weber E, McMahon M, Williams JR, Baylin S, Mal A, Harter ML, Dillehay LE, Claudio PP, Giordano A, Nelkin BD and Mabry M . (1998). J. Clin. Invest., 101, 153–159.
Roovers K, Davey G, Zhu X, Bottazzi ME and Assoian RK . (1999). Mol. Biol. Cell, 10, 3197–3204.
Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, van Belle P, Elder DE and Herlyn M . (2003). Cancer Res., 63, 756–759.
Sauter ER and Herlyn M . (1998). Mol. Carcinog., 23, 132–143.
Sauter ER, Yeo U-C, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M and Bastian BC . (2002). Cancer Res., 62, 3200–3206.
Schwartz MA . (1997). J. Cell Biol., 139, 575–578.
Scott G, Ryan DH and McCarthy JB . (1992). J. Invest. Dermatol., 99, 787–794.
Sherr CJ . (1996). Science, 274, 1672–1677.
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J and Arteaga CL . (2002). Nat. Med., 8, 1145–1152.
Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K and Kawakami Y . (2004). Oncogene, 12, 6031–6039.
Takano N, Kawakami T, Kawa Y, Asano M, Watabe H, Ito M, Soma Y, Kubota Y and Mizoguchi M . (2002). Pigment Cell Res., 15, 192–200.
Treinies I, Paterson HF, Hooper S, Wilson R and Marshall CJ . (1999). Mol. Cell. Biol., 19, 321–329.
Viglietto G, Motti ML and Fusco A . (2002). Cell Cycle, 1, 394–400.
Wantanabe G, Howe A, Lee RJ, Albanese C, Shu I-W, Karnezis AN, Zon L, Kyriakis J, Rundell K and Pestell RG . (1996). Proc. Natl. Acad. Sci. USA, 93, 12861–12866.
Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ and Marais R . (2004). Cancer Res., 64, 2338–2342.
Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA and Assoian RK . (2001). Nat. Cell Biol., 3, 950–957.
Zhu J, Woods D, McMahon M and Bishop JM . (1998). Genes Dev., 12, 2997–3007.
Zhu X, Ohtsubo M, Bohmer RM, Roberts JM and Assoian RK . (1996). J. Cell Biol., 133, 391–403.
Acknowledgements
We are indebted to the staff of The Birth Place at Albany Medical Center for providing discarded tissue samples for melanocyte isolation. We are very grateful to Drs Alan Howe, Stephen Keyse, Richard Marais and Martin McMahon for cDNA constructs and Dr Meenhard Herlyn for melanoma cell lines. Also, we thank Dr Michael DiPersio (Center for Cell Biology and Cancer Research, Albany Medical College) for his critical reading of the manuscript. This work was supported by National Institutes of Health Grants GM067893 (to AEA), CA81419 (to KP), and an institutional predoctoral training grant (T32-HL-07194).
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Bhatt, K., Spofford, L., Aram, G. et al. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 24, 3459–3471 (2005). https://doi.org/10.1038/sj.onc.1208544
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208544
Keywords
This article is cited by
-
ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma
Oncogene (2024)
-
Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer
Scientific Reports (2019)
-
RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1
Oncogene (2018)
-
14-3-3β Depletion Drives a Senescence Program in Glioblastoma Cells Through the ERK/SKP2/p27 Pathway
Molecular Neurobiology (2018)
-
Extracellular signal-regulated kinases 1/2 and Akt contribute to triclosan-stimulated proliferation of JB6 Cl 41-5a cells
Archives of Toxicology (2015)